You are here

bladder cancer

Immunitybio slumps as FDA declines to approve bladder cancer treatment

NASDAQ

Thu, 05/11/23 - 09:58 am

GSK's bellwether Zantac court date pushed to July

Endpoints

Sun, 02/26/23 - 10:11 pm

A renewed push into early bladder cancer

EP Vantage

Thu, 02/2/23 - 10:24 am

Ferring Pharmaceuticals

Ferring wins FDA approval for bladder cancer gene therapy

BioPharma Dive

Tue, 12/20/22 - 11:07 am

Ferring Pharmaceuticals

UroGen reports data from Phase IIb trial of bladder cancer treatment

Clinical Trials Arena

Mon, 12/5/22 - 10:51 am

clinical trials

Roche Withdraws Tecentric for Bladder Cancer Indication

BioSpace

Tue, 11/29/22 - 11:06 am

metastatic bladder cancer

A startup plans an IPO to give a shelved Lilly drug another shot

BioPharma Dive

Wed, 10/19/22 - 10:39 am

Acrivon Therapeutics

endometrial cancer

precision medicine

Modified bladder cancer treatment shows promise

Drugs.com

Tue, 08/23/22 - 10:29 pm

Texas Biomedical Research Institute

ImmunityBio’s Bladder Cancer Immunotherapy BLA gets FDA Nod

BioSpace

Mon, 08/1/22 - 10:29 am

Seagen, Astellas claim positive results in study key to cancer drug's success

BioPharma Dive

Tue, 07/26/22 - 11:26 am

clinical trials

Sesen slams brakes on phase 3 bladder cancer program to save cash as it looks for off-ramp

Fierce Biotech

Mon, 07/18/22 - 07:15 pm

clinical trials

ImmunityBio’s Patrick Soon-Shiong Discusses Quest to Orchestrate NK and T Cells

BioSpace

Thu, 06/16/22 - 10:21 am

Pantrick Soon-Shiong

Bristol Myers scraps $2B Nektar partnership after trial failures

BioPharma Dive

Mon, 04/18/22 - 11:42 pm

Bristol Myers Squibb

Nektar Therapeutics

BMS and Nektar Shutter Combination Cancer Development Program

BioSpace

Fri, 04/15/22 - 01:42 pm

Bristol Myers Squibb

Nektar Therapeutics

renal cell carcinoma

bempegaldesleukin

Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer

Pharmaforum

Mon, 02/14/22 - 11:44 pm

clinical trials

Merck's Keytruda survives FDA scrutiny in bladder cancer, but ends up with a smaller label

Fierce Pharma

Wed, 09/1/21 - 01:26 pm

FDA rejects Sesen Bio's bladder cancer pitch, sending shares spiraling back to penny stock territory

Endpoints

Sun, 08/15/21 - 11:01 pm

SeaGen builds cancer drug pipeline with China biotech deal

BioPharma Dive

Mon, 08/9/21 - 11:47 pm

Seagen, Astellas' Padcev snares full approval and expands into second-line treatment on path to blockbuster land

Fierce Pharma

Sat, 07/10/21 - 12:00 am

Roche joins the FDA accelerated approval revamp team, nixing a Tecentriq bladder cancer nod

Fierce Pharma

Mon, 03/8/21 - 11:12 am

Pages